| Attention deficit hyperactivity disorder
Azstarys vs Quillivant XR
Side-by-side clinical, coverage, and cost comparison for attention deficit hyperactivity disorder.Deep comparison between: Azstarys vs Quillivant with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQuillivant has a higher rate of injection site reactions vs Azstarys based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Quillivant but not Azstarys, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Azstarys
Quillivant
At A Glance
Oral
Daily
CNS stimulant
Oral
Daily
CNS stimulant
Indications
- Attention deficit hyperactivity disorder
- Attention deficit hyperactivity disorder
Dosing
Attention deficit hyperactivity disorder (ages 6-12) Starting dose 39.2 mg/7.8 mg orally once daily in the morning; may increase to 52.3 mg/10.4 mg or decrease to 26.1 mg/5.2 mg after one week; maximum 52.3 mg/10.4 mg once daily.
Attention deficit hyperactivity disorder (ages 13-17 and adults) Starting dose 39.2 mg/7.8 mg orally once daily in the morning; increase after one week to 52.3 mg/10.4 mg once daily depending on response and tolerability; maximum 52.3 mg/10.4 mg once daily.
Attention deficit hyperactivity disorder Starting dose 20 mg once daily in the morning for patients 6 years and above; may titrate weekly in increments of 10 mg to 20 mg; daily doses above 60 mg have not been studied and are not recommended.
Contraindications
- Known hypersensitivity to serdexmethylphenidate, methylphenidate, or other components of AZSTARYS
- Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of MAOI treatment
- Hypersensitivity to methylphenidate or other components of QUILLIVANT XR
- Concomitant or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs)
Adverse Reactions
Most common (>=5%) Decreased appetite, decreased weight, nausea, abdominal pain, dyspepsia, vomiting, insomnia, anxiety, affect lability, irritability, dizziness, increased blood pressure, tachycardia
Postmarketing Pancytopenia, thrombocytopenia, angina pectoris, bradycardia, supraventricular tachycardia, hepatocellular injury, acute hepatic failure, angioedema, anaphylactic reactions, urticaria, convulsion, serotonin syndrome, dyskinesia, hallucination, mania, rhabdomyolysis, priapism, Raynaud's phenomenon, alopecia
Most common (>=2%) affect lability, excoriation, initial insomnia, tic, decreased appetite, vomiting, motion sickness, eye pain, rash
Postmarketing pancytopenia, thrombocytopenia, angina pectoris, bradycardia, severe hepatocellular injury, angioedema, anaphylactic reactions, rhabdomyolysis, convulsion, dyskinesia, serotonin syndrome, hallucinations, mania, priapism, alopecia, Raynaud's phenomenon
Pharmacology
CNS stimulant prodrug combination; serdexmethylphenidate is a prodrug of dexmethylphenidate, which blocks reuptake of norepinephrine and dopamine into the presynaptic neuron and increases release of these monoamines into the extraneuronal space.
Methylphenidate is a CNS stimulant that blocks reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space; the mode of therapeutic action in ADHD is not fully known.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Azstarys
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
Quillivant
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Azstarys
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (5/8)
Quillivant
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Azstarys
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Quillivant
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Azstarys.
No savings programs available for Quillivant.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AzstarysView full Azstarys profile
QuillivantView full Quillivant profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.